This is the foundational cause of GLP-1 constipation
As reported in a randomized controlled trial, two patients with advanced liver disease, out of 69 patients in the simvastatin group, receiving simvastatin 40 mg/day experienced rhabdomyolysis, with no such sign found in the placebo group (Abraldes et al., 2016)
Strengths and limitations The primary strength of this review lies in its multidimensional framework, integrating high-quality randomized controlled trials, real-world evidence, regulatory documents, and expert consensus to support a phenotype- and complication-oriented treatment strategy for obesity
Russell, I
also underscored the importance of continued monitoring for adverse effects during long-term tirzepatide use [7]
Each dose was taken with no more than 120 mL/4 oz of water